Some of our osteosarcoma PDX models present an amplification of MYC (GR-OS-15), VEGFRA (GR-OS-17), or a pathogenic variant in PTEN (GR-OS-18), for which Genome-Informed Targeting has already been proven with CDK9 inhibitors, multikinase inhibitors or anti-VEGF, and AKT or mTOR inhibitors, respectively (12). Here, MYC is linked to osteosarcoma.